Clinical Trials Logo

Adrenal Insufficiency clinical trials

View clinical trials related to Adrenal Insufficiency.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05827965 Active, not recruiting - Clinical trials for Fasting, Intermittent

Ramadan Fasting in Secondary Adrenal Insufficiency Patients

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Intermittent Ramadan fasting was associated with a risk of complications in patients with adrenal insufficiency. A risk stratification with recommendations (lifestyle and drug adjustment) for fasting in these patients has been recently published. So, this prospective interventional study was carried out to evaluated these recommendations. Patients with secondary adrenal insufficiency and willing to fast Ramadan were included. Before Ramadan, patients underwent a clinical examination and were educated for lifestyle measures and the schedule of glucocorticoid replacement therapy was adjusted. The occurrence of complications and the number of fasted days during the month of Ramadan 2023 were reported and compared with those of Ramadan 2022.

NCT ID: NCT05741762 Active, not recruiting - Critical Illness Clinical Trials

Assessing Baseline Cortisol Levels in Patients Admitted With Septic Shock in Intensive Care Unit

Start date: January 31, 2023
Phase:
Study type: Observational

Critical illness-related corticosteroid insufficiency (CIRCI), a term coined since 2008 by Society of Critical Care Medicine (SCCM), and is characterized by inflammation resulting from inadequate intracellular glucocorticoid-mediated anti-inflammatory activity leading to increased morbidity and mortality in Intensive Care Unit (ICU) patients.1 Severe Sepsis with shock is a common reason for admission to ICU/hospital and may require ionotropic support.2 The current guidelines from SCCM in 2017 suggest using either random cortisol of < 10 ug/dL (<276 nmol/L) or change in cortisol at 60 min after cosyntropin (250 µg) administration from baseline cortisol of <9 µg/dl (<248 nmol/L) to assess of presence of CRCI and recommend use of hydrocortisone in these patients.3 There have been studies done to look at baseline cortisol in patient with severe pneumonia requiring ICU and they have found cortisol level of < 15 ug/dl (<414 nmol/L) can predict CIRCI.4 However, there is no study on assessment of baseline random cortisol levels in patients with septic shock in our local population. The current guidance from Surviving Sepsis campaign suggests a more clinical approach of adding IV corticosteroids only if there is ongoing requirement for vasopressors, which is a new change in contrast to 2016 guidelines.5 This study aims to look the available mean baseline cortisol in these patients to create a reference data for local population.

NCT ID: NCT05222152 Active, not recruiting - Clinical trials for Primary Adrenal Insufficiency

Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency

CHAMPAIN
Start date: November 23, 2021
Phase: Phase 2
Study type: Interventional

This study is a double-blind, double-dummy, two-way cross-over, randomised, Phase II study to be conducted at approximately 6 investigational sites in 2 countries. The study will compare the efficacy, safety and tolerability of twice daily Chronocort, a modified-release hydrocortisone, with once daily Plenadren, a modified-release hydrocortisone, over a treatment period of up to 2 months in participants aged 18 years and over, diagnosed with primary Adrenal Insufficiency (AI).

NCT ID: NCT04642391 Active, not recruiting - Cirrhosis Clinical Trials

Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis

Start date: August 2, 2021
Phase:
Study type: Observational

This study aims to define the prevalence and potential pathophysiologic mechanisms underlying relative adrenal insufficiency (RAI) in outpatients with decompensated cirrhosis. Patients will be followed prospectively for up to two years to determine incidence of RAI, whether RAI represents a permanent or dynamic physiologic state in cirrhosis, and to determine whether RAI in this setting is associated with important clinical outcomes.

NCT ID: NCT04519580 Active, not recruiting - Clinical trials for Adrenal Insufficiency

Improved Diagnostics and Monitoring of Polymyalgia Rheumatica

Start date: September 14, 2020
Phase:
Study type: Observational

Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects. PMR is an exclusion diagnosis, and methods to diagnose and monitor the disease are lacking. Objective: To investigate if ultrasound and PET/CT can be used to diagnose and monitor PMR. In addition, the importance of prednisolone induced adrenal insufficiency is investigated. Methods: It is a prospective observational study in patients suspected of PMR. Patients diagnosed with PMR continue in the study. Ultrasound and PET/CT are performed at baseline, after 8 weeks on prednisolone, and after 10 weeks during a short prednisolone break. Adrenal insufficiency is investigated five times throughout the study. After one year the PMR diagnosis is confirmed.

NCT ID: NCT03936517 Active, not recruiting - Clinical trials for Adrenal Insufficiency

Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)

PRED-AID
Start date: July 31, 2019
Phase: Phase 3
Study type: Interventional

This study compares low-dose prednisolone therapy against standard regimens of hydrocortisone therapy for the treatment of adrenal insufficiency (AI). AI is a condition in which, individuals are unable to sufficiently produce the natural stress hormone, cortisol.

NCT ID: NCT03793114 Active, not recruiting - Clinical trials for Primary Adrenal Insufficiency

Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease

Start date: September 26, 2018
Phase: N/A
Study type: Interventional

In autoimmune adrenal insufficiency, or Addison's disease (AD), the immune system attacks the adrenal cortex. As a result, the adrenal cells producing hormones such as cortisol and aldosterone are destroyed, leaving the body with insufficient levels to meet its needs. The common perception is that upon diagnosis of Addison's disease, basically all adrenal hormone production has ceased. There have, however, been found a few individuals who preserve some residual secretion of cortisol even years after diagnosis. The objectives of this study is to find out how common it is, and to explore if residual function have impact on patient outcome. That is, do patients with and without residual function differ when it comes to quality of life, working ability, medication dosages, and risk of adrenal crisis?

NCT ID: NCT03410160 Active, not recruiting - Clinical trials for Adrenal Insufficiency

Predisposing Factors for the Incidence of Adrenal Crisis

PIA
Start date: November 2015
Phase:
Study type: Observational

Within this clinical study patients with chronic adrenal insufficiency will be investigated by clinical and biochemical examination as well as questionnaire to identify predisposing factors for adrenal crisis.